Common use of Service description and background Clause in Contracts

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim for payment for the service. 1.9. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. centres • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim (by completing and submitting the consultation form) for payment for the service. 1.9. The pilot will commence in the geographies of East of England North, Greater Manchester, Peninsula, South East London, and Thames Valley Cancer Alliances only from June 2023. 1.10. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. centres • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim for payment for the service. 1.9. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. centres • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim for payment for the service. 1.9. The pilot will commence in the geographies of East of England North, Greater Manchester, Peninsula, South East London, and Thames Valley Cancer Alliances only from June 2023. 1.10. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. centres • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim for payment for the service. 1.9. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.

Service description and background. ‌ 1.1. This pilot will specifically evaluate the implementation by community pharmacy of direct referrals to secondary care diagnostics/Rapid Diagnostic Service (RDS) triage teams for people with suspected cancer signs and symptoms. The pilot will initially focus on testing safety and technical feasibility with a small number of Community Pharmacies before expanding to full pilot roll out and data collection to evaluate the benefits of direct referrals from Community Pharmacy for people presenting with suspected cancer symptoms. 1.2. Developing a direct referral service from community pharmacy to secondary care diagnostics/RDS triage teams for people with suspected cancer symptoms has the potential to improve patient outcomes and reduce health inequalities. It is hoped it will support the NHS Long Term Plan’s aims of 75% of cancer patients being diagnosed at Stage 1 or 2. 1.3. NHS England (NHSE) is commissioning this pilot as a Local Pharmacy Enhanced Service. 1.4. The key objectives of this pilot are: • To test the feasibility and acceptability of referral routes into secondary care and diagnostic centres. centres • To undertake quantitative and qualitative evaluation including patient experience and the experience of community pharmacy, primary and secondary care/RDS teams. • To test a new funding model, which aims to fairly remunerate provision of a quality service. 1.5. The decision to refer will be made during the consultation with the patient in the pharmacy consultation room, so that the appropriate next steps can be organised within a single episode of care. 1.6. Upon the patient’s presentation at the pharmacy, the pharmacist will conduct an appropriate clinical assessment (using the referral criteria outlined in the clinical protocol) in the pharmacy consultation room and record the consultation notes and make the referral (if needed). An online MS Form will be used to capture the consultation. 1.7. The clinical assessment would result in one of three outcomes based on the referral criteria, namely: a) The individual does not meet the referral criteria b) The individual meets the criteria for onward investigation in Primary Care c) The individual meets the referral criteria for referral to secondary care/RDS 1.8. The pharmacist submits a claim (by completing and submitting the consultation form) for payment for the service. 1.9. An evaluation of the service will be undertaken to facilitate a robust review and financial appraisal for NHS commissioners. The evaluation will examine the role of community pharmacists in referring individuals with suspected cancer symptoms and carry out a qualitative assessment of patient experience and pharmacy staff experience. It will also look at the wider service model and outcomes of referrals made.